Another Major DLL3 ADC Alliance As Hengrui Links With IDEAYA

The new year has already brought multiple deals for China-originated antibody-drug conjugates in the DLL3 class, which companies in the country dominate.

Lung cancer
Chinese DLL3 ADCs nearly monopolize the class. • Source: Shutterstock

More from Deals

More from Immuno-oncology